
Ovusense
Real-time fertility monitoring with continuous core body temperature.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
investor | €0.0 | round | |
$250k | Debt | ||
Total Funding | 000k |
Related Content
Ovusense is a brand of fertility monitoring solutions developed by viO HealthTech, a company formerly known as Fertility Focus, which was founded in 2006. The technology was created by Dr. Andy Butterworth and Professor Toby Knowles from the University of Bristol and licensed to their spin-out company. Rob Milnes serves as the CEO of viO HealthTech, motivated by his personal experiences with fertility challenges.
The company operates in the Femtech sector, offering a direct-to-consumer business model through its website and mobile apps. Revenue is generated from the sale of its fertility monitoring devices and accompanying subscription services for data analysis and support. Ovusense is a Class 2 registered medical device, holding certifications in Europe (CE mark), the USA (FDA 510(k)), Canada (CMDCAS), and Australia (TGA).
The core product is a fertility monitoring system that uses patented technology to track continuous Core Body Temperature (cCBT) to predict and confirm ovulation. The system includes a sensor and a companion app. The primary sensor, OvuCore, is a medical-grade silicone sensor worn vaginally overnight. It measures core body temperature every five minutes to track the hormonal shifts associated with ovulation, particularly the rise in progesterone. This data is downloaded to the app each morning, which then provides a prediction of ovulation up to 24 hours in advance and confirms the exact date with up to 99% accuracy. The technology is designed to be particularly effective for women with irregular cycles or conditions like Polycystic Ovary Syndrome (PCOS).
In addition to the OvuCore, the company offers OvuFirst, a skin-worn sensor for women with regular cycles, and OvuSense Pro, a portal for clinicians to remotely monitor patients and their treatment. In early 2022, the parent company rebranded from Fertility Focus to viO HealthTech, signaling an expansion from fertility to broader women's health issues, including menopause and pregnancy complications, leveraging the data from over 210,000 tracked cycles.
Keywords: fertility monitor, ovulation tracking, core body temperature, Femtech, medical device, cCBT, OvuCore, PCOS, conception aid, reproductive health, cycle tracking, viO HealthTech, progesterone monitoring, fertility sensor, real-time ovulation prediction, at-home fertility test, women's health technology, digital therapeutics, pregnancy planning, irregular cycles